Dual activity of serum lipoprotein-associated phospholipase A 2 yielding positive and inverse associations with cardiometabolic risk

Clinical Chemistry and Laboratory Medicine

Volumn 49, Issue 8, 2011, Pages 1349-1357

  Onat, Altan ^a,b   Hergenç, Gülay ^c   Can, Günay ^b   Ugǎur, Murat ^d   Nartop, Filiz ^e  

^a Turkish Society of Cardiology   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

^c YILDIZ TECHNICAL UNIVERSITY   (Turkey)

^d DR SIYAMI ERSEK THORACIC AND CARDIOVASCULAR SURGERY TRAINING AND RESEARCH HOSPITAL   (Turkey)

^e GOZTEPE TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

atherogenic dyslipidemia; coronary heart disease; diabetes type 2; lipoprotein associated phospholipase A 2 mass

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN C3; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD PRESSURE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; CORONARY RISK; DYSLIPIDEMIA; ENZYME ACTIVITY; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK ASSESSMENT; SEX DIFFERENCE; TURKEY (REPUBLIC); WAIST CIRCUMFERENCE;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADULT; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; LOGISTIC MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; ODDS RATIO; PROTEIN BINDING; RISK FACTORS; SEX FACTORS;

EID: 80051708262     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2011.110     Document Type: Article

References (33)

1. Anderson JL. Lipoprotein-associated phospholipase A2: An independent predictor of coronary artery disease events in primary and secondary prevention. Am J Cardiol 2008;101(Suppl): 23F-33F.
2. Kolodgie FD, Burke AP, Skorija KS, Ladich E, Kutys R, Makuria AT, et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 2006;26:2523-9. (Pubitemid 44607475)
3. Weintraub HS. Identifying the vulnerable patient with ruptureprone plaque. Am J Cardiol 2008;101(suppl):3F-10F.
4. Carlquist JF, Muhlestein JB, Anderson JL. Lipoprotein-associated phospholipase A2: A new biomarker for cardiovascular risk assessment and potential therapeutic target. Expert Rev Mol Diagn 2007;7:511-7. (Pubitemid 47547719)
5. Persson M, Hedblad B, Nelson JJ, Berglund G. Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects. Arterioscler Thromb Vasc Biol 2007;27:1411-6. (Pubitemid 46823453)
6. Rana JS, Arsenault BJ, Després J-P, CǒtéM, Talmud PJ, Ninio E, et al. Inflammatory biomarkers, physical activity, and risk of future coronary heart disease in healthy men and women. Eur Heart J 2009;92:336-44.
7. McLaughlin TM, Abbasi F, Wolfert R, Lamendola C, Reaven G, Reaven P. Lipoprotein-associated phospholipase A2 is not increased in association with insulin resistance wabstractx. Arterioscler Thromb Vasc Biol 2004;24:E-67.
8. Kim JY, Hyun YJ, Jang Y, Lee BK, Chae JS, Kim SE, et al. Lipoprotein-associated phospholipase A2 activity is associated with coronary artery disease and markers of oxidative stress: A case-control study. Am J Clin Nutr 2008;88:630-7.
9. Lerman A, McConnell JP. Lipoprotein-associated phospholipase A2: A risk marker or a risk factor? Am J Cardiol 2008;101 (suppl):11F-22F.
10. Tselepis AD, Karabina SP, Stengel D, Piédagnel R, Chapman MJ, Ninio E. N-linked glycosylation of macrophage-derived PAF-AH is a major determinant of enzyme association with plasma HDL. J Lipid Res 2001;42:1645-54. (Pubitemid 33020097)
11. Marathe GK, Zimmerman GA, McIntyre TM. Platelet-activating factor acetylhydrolase, and not paraoxonase-1, is the oxidized phospholipids hydrolase of high-density lipoprotein particles. J Biol Chem 2003;278:3937-47. (Pubitemid 36801125)
12. Onat A, Ceyhan K, Basar Ö, Erer B, Toprak S, Sansoy V. Metabolic syndrome: Major impact on coronary risk in a population with low cholesterol levels -a prospective and cross-sectional evaluation. Atherosclerosis 2002;165:285-92. (Pubitemid 35339372)
13. Onat A. Risk factors and cardiovascular disease in Turkey. Atherosclerosis 2001;156:1-10. (Pubitemid 32429589)
14. Onat A, Hergenç G. Low-grade inflammation and dysfunction of high-density lipoprotein and its apolipoproteins as a major driver of cardiometabolic risk. Metabolism 2010;60:499-512.
15. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, et al. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Expert Committee on the Diagnosis and Classification of Diabetes mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003;26:3160-7.
16. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). J Am Med Assoc 2001;285: 2486-97.
17. Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004;109:433-8. (Pubitemid 38133916)
18. Onat A, Uyarel H, Hergenç G, Karabulut A, Albayrak S, Can G. Determinants and definition of abdominal obesity as related to risk of diabetes, metabolic syndrome and coronary disease in Turkish men: A prospective cohort study. Atherosclerosis 2007;191:182-90. (Pubitemid 46237629)
19. Rose G, Blackburn H, Gillum RF, Prineas RJ. Cardiovascular survey methods, 2nd ed. Geneva, Switzerland: WHO, 1982: 124-7.
20. Persson M, Nilsson JA, Nelson JJ, Hedblad B, Berglund G. The epidemiology of Lp-PLA2: Distribution and correlation with cardiovascular risk factors in population-based cohort. Atherosclerosis 2007;190:388-96. (Pubitemid 46074030)
21. Gerber Y, McConnell JP, Jaffe AS, Weston SA, Killian JM, Roger VL. Lipoprotein-associated phospholipase A2 and prognosis after myocardial infarction in the community. Arterioscler Thromb Vasc Biol 2006;26:2517-22. (Pubitemid 44607474)
22. Elkind MS, Tai W, Coates K, Paik MC, Sacco RL. High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2 and outcome after ischemic stroke. Arch Intern Med 2006; 166:2073-80. (Pubitemid 44631394)
23. Furberg CD, Nelson JJ, Solomon C, Cushman M, Jenny NS, Psaty BM. Distribution and correlates of lipoprotein-associated phospholipase A2 in an elderly cohort. J Am Geriatr Soc 2008;56:792-9. (Pubitemid 351652403)
24. Anuurad E, Ozturk Z, Enkhmaa B, Pearson TA, Berglund L. Association of lipoprotein-associated phospholipase A2 with coronary artery disease in African-Americans and Caucasians. J Clin Endocrin Metab 2010;95:2376-83.
25. Gardner AA, Reichert EC, Topham MK, Stafforini DM. Identification of a domain that mediates association of platelet-activating factor acetylhydrolase with high-density lipoprotein. J Biol Chem 2008;283:17099-106.
26. Samanta U, Bahnson BJ. Crystal structure of human plasma platelet activating factor acetyl hydrolase; structural implications to lipoprotein binding and catalysis. J Biol Chem 2008; 283:31617-24.
27. Onat A, HergençG, Bulur S, Uĝur M, Küçü kdurmaz Z, Can G. The paradox of high apolipoprotein A-I levels independently predicting incident type-2 diabetes among Turks. Int J Cardiol 2010;142:72-9.
28. Onat A, Can G, Ayhan E, Kaya Z, Hergenç G. Impaired protection against diabetes and coronary disease by high-density lipoproteins in Turks. Metabolism 2009;58:1393-9.
29. Onat A, Hergenç G, Ayhan E, Uĝur M, Kaya H, Tuncer M, et al. Serum apolipoprotein C-III in high-density lipoprotein: A key diabetogenic risk factor among Turks. Diabet Med 2009;26:981-8.
30. Noto H, Chitkara P, Raskin P. The role of lipoprotein-associated phospholipase A2 in the metabolic syndrome and diabetes. J Diabetes Complicat 2006;20:343-8. (Pubitemid 44633698)
31. Hergenç G, Onat A, Sari I, Yazici M, Eryonucu B, Can G. Serum total and high-density lipoprotein phospholipid levels in a population-based study and relationship to risk of metabolic syndrome and coronary disease. Angiology 2008;59:26-35. (Pubitemid 351253076)
32. Garza CA, Montori VM, McConnell JP, Somers VK, Kullo JJ, Lopez-Jimenez F. Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: A systematic review. Mayo Clin Proc 2007;82:159-65. (Pubitemid 46198473)
33. Onat A, HergençG, Kelȩs I, Doĝan Y, Türkmen S, Sansoy V. Sex difference in development of diabetes and cardiovascular disease on the way from obesity and metabolic syndrome: Prospective study of a cohort with normal glucose metabolism. Metabolism 2005;54:800-8. (Pubitemid 40731508)